Aptamer Group Plc · LSE:APTA
Aptamer — FY2024 Earnings Presentation
17 slides from Aptamer's earnings presentation, June 2024
Slide 1: Aptamer Group plc Full year results for twelve months to 30 June 2024
Aptamer Group plc Full year results for twelve months to 30 June 2024 Investor presentation
Slide 2: Disclaimer
DISCLAIMER This presentation (“Presentation”) contains forward-looking statements, including in relation to the financial position and prospects of Aptamer Group plc (“Company”) and its group (“Group”). These forward-looking statements are not based on historical facts but rather on expectations and
Slide 3: Presentation team
Presentation team Andrew Rapson Dr Arron Tolley Chief Financial Chief Executive Officer Officer ‒ Co-founded Aptamer Group in 2008 ‒ Over 20 years of finance experience, ‒ Globally-recognised technical and including AIM listed companies commercial leader in aptamers ‒ Chartered Accountant ‒ Delivere
Slide 4: Business overview
Business overview Recognised as a key global player in aptamer development 1 Proprietary Optimer® platform to deliver antibody alternatives Relationships with all the Top 10 global pharma companies 2 - Incorporated in 2008 - Headquartered in York, UK - AIM IPO in Dec 2021 - State-of-the-art faciliti
Slide 5: Technical advantages of our platforms
Technical advantages of our platforms Broader target applicability Tuneable selectivity and tailored to end application Speed of discovery Scalable cost-effective production Synthetic manufacture allows better quality control Optimer® are optimised Proprietary, fully-controlled, patent portfolio DNA
Slide 6: Commercial applications across the life science sector and beyond
Commercial applications across the life science sector and beyond Therapeutics Diagnostics Addressing a $170bn market for affinity ligands.1 The Optimer® platform has diverse applications across the life sciences in therapeutics, diagnostics, bioprocessing, and research. Increased recognition of our
Slide 7: High value Optimer assets
High value Optimer® assets Optimer® developed as potential Developing Optimer®-based Optimer® delivery vehicle active ingredient in deodorants lateral flow test for early validated for potential precision Alzheimer’s disease test Optimer® for deodorant with patent filed in 2024. diagnosis of Alzheim
Slide 8: Financial review
Financial review
Slide 9: Income statement
Income statement • Group revenue of £0.9m (2023: £1.8m) Year ended Year ended • £0.3m H1 and £0.6m H2 30 Jun ‘24 30 Jun ‘23 • £1.0m signed deals in Q4 £’000 £’000 Revenue 860 1,752 • Admin expenses £3.2m (2023: £5.0m) Cost of Sales (610) (1,393) • Cost base restructured in Q1 Gross profit 250 359 •
Slide 10: Balance sheet
Balance sheet Year ended Year ended • Net assets of £0.9m (2023: £0.3m) 30 Jun 24 30 Jun 23 • Equity raises in August and September 2023 £’000 £’000 raising net proceeds of £3.2m and £0.3m Other intangible assets 165 70 respectively Property, plant & equipment 424 561 • 370m shares issued at 1p in A
Slide 11: Operational and post-period review
Operational and post-period review
Slide 12: Operational highlights
Operational highlights – New strategic approach focused on the development and partnering of high-value Optimer® assets. – Group reorganisation and cost base reduced to enable strategy delivery. – Commercial pipeline rebuilt over the period with increasing revenue momentum in the second half of the
Slide 13: Post-period highlights
Post-period highlights – Successful fundraise in August 2024 of £2.6m (net). – Refreshed Board to support Group refocusing on Optimer® asset development. – Completed development of Optimer® delivery vehicle for genetic medicine project signed in December 2023. Material shipped to the partner for tes
Slide 14: Board
Board Dr Adam Dr Arron Tolley Andrew Rapson Dr David Bunka Tim Sykes Hargreaves Chief Executive Chief Financial Chief Scientific Non-Exec Non-Exec Officer Officer Officer director Chair ‒ Co-founder & established ‒ Over 20 years finance ‒ Co-founder & globally ‒ Founder & Director of drug ‒ Experien
Slide 15: Delivering growth
Delivering growth FY24 FY25 FY26 Deodorant Optimer® streamlined Proven in lab tests in-house Patent filed in Contract extended for On-person functionality Project Potential Optimer® for performance & & at Unilever March 2024 on-person studies studies beginning in 2024 completion licensing if manufac
Slide 16: Investment case
Investment case Optimer® for deodorant Alzheimer’s diagnostic Drug delivery vehicles with with Unilever with NeuroBio AstraZeneca FFS arm targeting the $170bn 02 Developing high-value assets with strategic partners affinity ligand market1 to to target future licensing revenue meet demand for antibod
Slide 17: Questions?
we °° °° °°» Questions? @ aptamer